Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6106466 | Journal of Hepatology | 2011 | 13 Pages |
Atherosclerosis has been described as a liver disease of the heart [1]. The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus-host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3]. One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to:â¢update the hepatologist on lipid metabolismâ¢review the evidence that HCV exploits hepatic lipid pathways to its advantageâ¢discuss approaches to targeting host lipid pathways as adjunctive therapy.